| Budget Amount *help |
¥5,460,000 (Direct Cost: ¥4,200,000、Indirect Cost: ¥1,260,000)
Fiscal Year 2014: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2013: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2012: ¥2,600,000 (Direct Cost: ¥2,000,000、Indirect Cost: ¥600,000)
|
|---|
| Outline of Final Research Achievements |
Corneal dystrophy is genetic, progressive, and bilateral corneal dysorders leading to blindness. The only therapy on the corneal dystrophy is corneal transplantation. However, some of the patients can not receive corneal transplantation becaus of the lack of corneal donors in Japan, post-surgical complication, and recurrence of corneal dystrophy after corneal dystrophy.
In the present study, we have developed in vitro model of corneal dystrophy using the synthetic peptides corresponding to corneal dystrophy. Using thioflavin T, a amyloidphilic fluorescent reagent, was effective in the breakdown of the amyloid fibrils in the in vitro model of corneal dystrophy.
Thus, we have developed basic model of the photodynamic therapy on the corneal dystrophy.
|
